Condition: Osteosarcoma · Sarcoma · Sponsor: Hansoh BioMedical R&D Company
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory osteosarcoma and other sarcomas.
This description comes directly from the study's public registry record.
Wei Guo, MD · 010-88326656 · bonetumor@163.com
Cuicui Cong · 01088324516 · rmyyllwyh@163.com
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijing, China | Recruiting |
| Hunan Cancer Hospital | Changsha, China | Recruiting |
| First Affiliated Hospital, Sun Yat-Sen University | Guangzhou, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, China | Recruiting |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Recruiting |
| Chinese PLA General Hospital of Eastern Theater Command | Nanjing, China | Recruiting |
| Shanghai 6th People's Hospital | Shanghai, China | Recruiting |
| Shanghai General Hospital | Shanghai, China | Recruiting |
| Tianjin Cancer Hospital | Tianjin, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05830123